Cargando…

Biomarkers and risk factors for the early prediction of immune-related adverse events: a review

In recent years, immunotherapy has been widely used to treat patients with malignant tumors. While immune checkpoint inhibitors (ICIs) significantly improve the prognosis of cancer patients, the incidence of immune-related adverse events (irAEs) is increasing. Not only can irAEs accumulate in multip...

Descripción completa

Detalles Bibliográficos
Autores principales:	Zhang, Ying, Zhang, Xiaoling, Li, Weiling, Du, Yunyi, Hu, Wenqing, Zhao, Jun
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Taylor & Francis 2022
Materias:	Clinical – Review
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8986173/ https://www.ncbi.nlm.nih.gov/pubmed/35108160 http://dx.doi.org/10.1080/21645515.2021.2018894

Ejemplares similares

HER2-targeted advanced metastatic gastric/gastroesophageal junction adenocarcinoma: treatment landscape and future perspectives
por: Li, Weiling, et al.
Publicado: (2022)

Biomarkers, Clinical Features, and Rechallenge for Immune Checkpoint Inhibitor Renal Immune-Related Adverse Events
por: Isik, Busra, et al.
Publicado: (2021)

Predictive Biomarkers for Checkpoint Inhibitor Immune-Related Adverse Events
por: Les, Iñigo, et al.
Publicado: (2023)

PD-1 inhibitor treatment in a penile cancer patient with MMR/MSI status heterogeneity: A case report
por: Du, YunYi, et al.
Publicado: (2022)

Management of immune checkpoint inhibitor‐related rheumatic adverse events
por: Zhou, Jiaxin, et al.
Publicado: (2019)

Management of immune checkpoint inhibitor‐related dermatologic adverse events
por: Si, Xiaoyan, et al.
Publicado: (2019)

The biomarkers related to immune related adverse events caused by immune checkpoint inhibitors
por: Jia, Xiao-Hui, et al.
Publicado: (2020)

Clinical diagnosis and treatment recommendations for immune checkpoint inhibitor‐related hematological adverse events
por: Zhuang, Junling, et al.
Publicado: (2020)

The clinical application value of phase angle of six parts in nutritional evaluation of tumor patients
por: Zhang, Xiaoling, et al.
Publicado: (2022)

Clinical recommendations on diagnosis and treatment of immune checkpoint inhibitor‐induced renal immune‐related adverse events
por: Zheng, Ke, et al.
Publicado: (2020)

Management of immune-related cutaneous adverse events with dupilumab
por: Kuo, Alyce Mei-Shiuan, et al.
Publicado: (2023)

Mechanisms and biomarkers of immune-related adverse events in gastric cancer
por: Ding, Ping’an, et al.
Publicado: (2023)

Serological biomarkers predict immune-related adverse events and clinical benefit in patients with advanced gastrointestinal cancers
por: Wang, Yanni, et al.
Publicado: (2022)

Treatment-related adverse events and response rate to immune checkpoint inhibition
por: Li, Yanmin, et al.
Publicado: (2019)

Distinct T cell sub-clusters may serve as biomarkers for immune related adverse events
por: Jing, Ying, et al.
Publicado: (2023)

Association of antibiotic treatment with immune-related adverse events in patients with cancer receiving immunotherapy
por: Jing, Ying, et al.
Publicado: (2022)

External validation of biomarkers for immune-related adverse events after immune checkpoint inhibition
por: Glehr, Gunther, et al.
Publicado: (2022)

Endocrine‐related adverse events associated with immune‐checkpoint inhibitors in patients with melanoma
por: Kassi, Eva, et al.
Publicado: (2019)

Efficacy and immune-related adverse event associations in avelumab-treated patients
por: Kelly, Karen, et al.
Publicado: (2020)

Predictive Biomarkers of Severe Immune-Related Adverse Events With Immune Checkpoint Inhibitors: Prevention, Underlying Causes, Intensity, and Consequences
por: Cardeña-Gutiérrez, Ana, et al.
Publicado: (2022)

Peripheral Blood Biomarkers Predictive of Efficacy Outcome and Immune-Related Adverse Events in Advanced Gastrointestinal Cancers Treated with Checkpoint Inhibitors
por: Zhang, Zhening, et al.
Publicado: (2022)

Divergent tumor and immune cell reprogramming underlying immunotherapy response and immune-related adverse events in lung squamous cell carcinoma
por: Chen, Minjiang, et al.
Publicado: (2023)

The Role of Cytokines in Predicting the Response and Adverse Events Related to Immune Checkpoint Inhibitors
por: Wang, Min, et al.
Publicado: (2021)

Immune-Related Adverse Events: Pneumonitis
por: Zhong, Linda, et al.
Publicado: (2020)

Multi-omics prediction of immune-related adverse events during checkpoint immunotherapy
por: Jing, Ying, et al.
Publicado: (2020)

Analysis of characteristics and predictive factors of immune checkpoint inhibitor-related adverse events
por: Bai, Rilan, et al.
Publicado: (2021)

Biomarkers of Checkpoint Inhibitor Induced Immune-Related Adverse Events—A Comprehensive Review
por: Hommes, Josefien W., et al.
Publicado: (2021)

Biomarkers Associated with Immune-Related Adverse Events under Checkpoint Inhibitors in Metastatic Melanoma
por: Wölffer, Marcus, et al.
Publicado: (2022)

Lower baseline autoantibody levels are associated with immune-related adverse events from immune checkpoint inhibition
por: Ghosh, Nilasha, et al.
Publicado: (2022)

Selective immune suppression using interleukin-6 receptor inhibitors for management of immune-related adverse events
por: Fa'ak, Faisal, et al.
Publicado: (2023)

Immune-related adverse events: A bibliometric analysis
por: Jiang, Shi-Tao, et al.
Publicado: (2022)

Ophthalmic immune-related adverse events associated with immune checkpoint inhibitors
por: Gan, Linyang, et al.
Publicado: (2023)

Turicibacter and Acidaminococcus predict immune-related adverse events and efficacy of immune checkpoint inhibitor
por: Hamada, Kazuyuki, et al.
Publicado: (2023)

Ferritin as a diagnostic, differential diagnostic, and prognostic marker for immune-related adverse events
por: Zhang, Weihong, et al.
Publicado: (2021)

Biomarkers for gastrointestinal adverse events related to thiopurine therapy
por: Zudeh, Giulia, et al.
Publicado: (2021)

Clinical assessment of immune-related adverse events
por: Sosa, Aaron, et al.
Publicado: (2018)

Gastrointestinal disorders as immune-related adverse events
por: Balducci, Daniele, et al.
Publicado: (2021)

Vasospastic Angina: An Immune-related Adverse Event
por: Kumamoto, Taku, et al.
Publicado: (2021)

Immune-Related Adverse Events of the Gastrointestinal System
por: Nicolaides, Steven, et al.
Publicado: (2023)

Sorafenib-Related Adverse Events in Predicting the Early Radiologic Responses of Hepatocellular Carcinoma
por: Lee, Shou-Wu, et al.
Publicado: (2019)

Cannot write session to /tmp/vufind_sessions/sess_rcjogjf7qvpoigh1q3cnnpcu46